|
" Prostacyclin and Its Stable Analogue Iloprost "
edited by R.J. Gryglewski, G. Stock.
| Document Type
|
:
|
BL
|
| Record Number
|
:
|
728775
|
| Doc. No
|
:
|
b548528
|
| Main Entry
|
:
|
edited by R.J. Gryglewski, G. Stock.
|
| Title & Author
|
:
|
Prostacyclin and Its Stable Analogue Iloprost\ edited by R.J. Gryglewski, G. Stock.
|
| Publication Statement
|
:
|
Berlin, Heidelberg: Springer Berlin Heidelberg, 1987
|
| Page. NO
|
:
|
(xv, 314 pages 131 illustrations)
|
| ISBN
|
:
|
3540169547
|
|
|
:
|
: 3642714994
|
|
|
:
|
: 9783540169543
|
|
|
:
|
: 9783642714993
|
| Contents
|
:
|
Introduction, Chemistry, Receptor Interaction and Platelet Mechanisms --;The Impact of Prostacyclin Studies on the Development of Its Stable Analogues --;Chemistry of Stable Prostacyclin Analogues: Synthesis of Iloprost --;Prostaglandins, Thromboxanes and Platelet Function --;Effects of Iloprost on Platelet Activation In Vitro --;In Vitro Effects of Iloprost on Platelet Aggregation in Normal and Hypercholesterolemic Subjects --;Desensitization of Iloprost or Prostacyclin Responsiveness --;Resistance of Platelets to Prostacyclin --;Preliminary Comparison of the Effects of Iloprost, Prostacyclin (PGI2) and Prostaglandin E1 (PGE1) on Human Platelet Function --;Laboratory Investigations of Potential Heparin --;Iloprost Interactions --;Antithrombotic Profile of Iloprost in Experimental Models of Arterial and Venous Thrombosis --;Monitoring of Effectiveness of Prostaglandin Therapy in Humans --;Effect of Iloprost (ZK 36374) on White Cell Behavior --;Discussion --;Cardiovascular Pharmacology, Tissue Protection and Effects on Prostaglandin Synthesis --;Eicosanoid Expression of Vascular Sexual Dimorphism --;Profile of Generation of Eicosanoids by Blood Vessels and the Heart --;Studies on Vasorelaxant Effects and Mechanisms of Iloprost in Isolated Preparations --;Effects of Iloprost Treatment in the Rat on Prostacyclin Release from Isolated Aortas --;Electrical and Mechanical Effects of Prostacyclin in the Canine Carotid Artery --;Hemodynamic Profile of Iloprost in Rats, Rabbits and Cats --;Actions of Prostaglandins on the Heart --;Myocardial Ischemia: The Potential Therapeutic Role of Prostacyclin and Its Analogues --;Effects of Iloprost on Arrhythmias and Infarct Size in Rats After Coronary Artery Ligation --;The Protective Mechanism of Iloprost in Several Models of Jeopardizing Ischemia in the Myocardium --;Evolution Toward Necrosis During Intermittent Periods of Myocardial Ischemia: Cytoprotective Effects of Iloprost, a Stable Prostacyclin Analogue --;Protective Effects of Iloprost Against Thromboxane-Induced Myocardial Infarction --;Allograft Survival with Iloprost --;Iloprost in Experimental Cerebral Ischemia --;Cytoprotective Effect of Iloprost Against Liver Cell Death Induced by Carbon Tetrachloride (CCl4) or Bromobenzene --;Lipofundin Arteriosclerosis and Iloprost Treatment --;Discussion --;Personal Views --;Iloprost and Thrombosis Prevention --;Prostacyclin and Iloprost --;Thrombosis and Atherosclerosis --;The Reduction of Ultimate Infarct Size: State of the Art and Goals for the Future --;Iloprost and Cytoprotection --;Cardioprotective Effects of Iloprost --;Authors' Index.
|
| Abstract
|
:
|
Ten years after the discovery of prostacyclin, our knowledge of its biochemical mode of action, pharmacological properties, pathophysiological significance and therapeutic applications is ever expanding. Prostacyclin is both complex and unique as demonstrated by its unusual feature of being chemically and meta bolically unstable when compared to other prostanoids and known amine or peptide mediators. Although physiologically essential, the chemical instability of prostacyclin poses a serious drawback in laboratory and clinical studies. It is one of the genuine objectives of pharmaceutical research to supply synthetic compounds which overcome the inherent drawbacks - considering investigational and therapeutic use - of endogenous compounds. Whereas metabolic instability in certain cases could be of advantage, chemical instability definitely is not. With Iloprost, a molecule has been designed which - according to all data so far available - pertains high receptor affinity, metabolic instability (clinically this equates with a fine control of Iloprost's effects) while chemical stability has been achieved. By virtue of these characteristics Iloprost can be considered as one step towards specific interaction within the arachidonic acid cascade, namely the prostacyclin receptor. The aim of the symposium was to provide a critical experimental appraisal concerning the biochemical mode of action and pharmacological properties of prostacyclin and Iloprost.
|
| Subject
|
:
|
Cardiology.
|
| Subject
|
:
|
Medicine.
|
| Subject
|
:
|
Toxicology.
|
| LC Classification
|
:
|
RM666.P855E358 1987
|
| Added Entry
|
:
|
G Stock
|
|
|
:
|
R J Gryglewski
|
| |